TD Private Client Wealth’s Grace Therapeutics GRCE Stock Holding History

TD Private Client Wealth’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-40,132	Closed	-$110K	–	1252
2023 Q3	$110K	Sell	40,132 -1	-0%	-$2	﹤0.01%	631
2023 Q2	$126K	Hold	40,133	–	–	0.01%	625
2023 Q1	$111K	Buy	+40,133	New	+$143K	0.01%	635

Other funds holding GRCE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

IGWM

ICA Group Wealth Management Denver, Colorado $167M AUM 18.57% 1-Year Est. Return

TD Private Client Wealth's GRCE Position: Q4 2023 in Review

TD Private Client Wealth sold out of Grace Therapeutics (GRCE) in Q4 2023, closing a stake of 40,132 shares — an estimated $110K sold.

TD Private Client Wealth first reported a position in GRCE in Q1 2023 and held it in 3 quarters. The position peaked at $126K in Q2 2023. 9 funds tracked by Wall St. Rank hold GRCE as of Q4 2023.

TD Private Client Wealth reported no remaining Grace Therapeutics position as of Q4 2023 after selling out during the quarter.
TD Private Client Wealth sold 40,132 Grace Therapeutics shares in Q4 2023, an estimated $110K.
TD Private Client Wealth first reported a position in Grace Therapeutics in Q1 2023 and held it in 3 quarters.
TD Private Client Wealth's Grace Therapeutics position peaked at $126K in Q2 2023.
9 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2023.

Based on TD Private Client Wealth's 13F filing for Q4 2023, filed 16 Aug 2024.